New chemo cocktail aims to tackle rare brain tumors
NCT ID NCT07188441
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of two chemotherapy drugs, teniposide and cisplatin, in 40 people newly diagnosed with central malignant germ cell tumors. The goal is to see if the combo is safe and effective at shrinking tumors and prolonging survival. Researchers will also look for biomarkers that might predict who benefits most.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- teniposide and cisplatin
- What this could lead to
- If successful, this combination could offer a new treatment option to control central malignant germ cell tumors and extend survival.
- What could go wrong
- This is a small, early-phase trial with only 40 participants and no comparison group, so results may not be definitive. Side effects from chemotherapy are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2024
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
5 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Must have at least one measurable lesion defined by RANO criteria * The initial diagnosis has been confirmed as central malignant germ cell tumor * Expected survival period ≥ 6 months * Absolute neutrophil ≥1.0×10\^9/L; Platelet ≥100.0×10\^9/L * Aspertate aminotransferase and alanine aminotransferase ≤2.5×Upper limit of normal * total bilirubin ≤1.5×Upper limit of normal * Electronic Case Report of Form≥70mL/min/1.73m\^2 * Estimated glomerular filtration rate ≥ 70 mL/min/1.73 m² or normal serum creatinine (Cr) * Women and men with fertility must agree to use appropriate contraceptive methods (hormones or barrier therapy or abstinence) during the study period and within 3 months after the last dose; The pregnancy test of female subjects of childbearing age within 7 days before administration must be negative * Willing and able to read, understand, and sign written informed consent, parents/guardians of child or adolescent subjects have the ability to understand, agree, and sign research informed consent forms and applicable child consent forms before initiating any protocol related procedures Exclusion Criteria: * Patients undergoing any other anti-cancer experimental treatment * Individuals with a history of severe allergies or allergies to any component of the drugs in the past * Previous or concurrent active cardiovascular diseases with clinical significance, including congenital heart disease or pericardial disease, history of heart failure, myocardial infarction, coronary heart disease, heart valve disease, cardiomyopathy, and arrhythmia * Patients with Magnetic Resonance Imaging contraindications * Those who need to receive live virus vaccine during administration * Serious complications and/or underlying diseases * Individuals with poor control of hypertension (under standardized blood pressure reduction protocols, systolic blood pressure ≥ 160mmHg and/or diastolic blood pressure ≥ 100mmHg) * Uncontrolled systemic bacterial, viral, or fungal infections * Patients infected with Human Immunodeficiency Virus(HIV) or syphilis * Patients who have undergone organ transplantation in the past * Pregnant or lactating women * Researchers believe that there are other factors that are not suitable for participating in the experiment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Central malignant germ cell tumor are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a faster chemo schedule beat tough testicular cancer?
- High-Dose chemo with stem cell transplant tested against standard therapy for tough germ cell cancers
- Could a dementia drug shield kids' brains from radiation damage?
- Dietary change explored as cancer support strategy
- Hypnosis may ease chemo anxiety in teens and young adults
- Could a simple pill keep relapsed testicular cancer at bay?